Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells.

Abe Y, Ijichi N, Ikeda K, Kayano H, Horie-Inoue K, Takeda S, Inoue S.

Cancer Sci. 2012 Apr;103(4):806-12. doi: 10.1111/j.1349-7006.2012.02201.x. Epub 2012 Feb 7.

2.

Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.

Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Horm Cancer. 2012 Aug;3(4):147-59. doi: 10.1007/s12672-012-0111-0. Epub 2012 Apr 3.

PMID:
22476979
3.

Forkhead-box A1 suppresses the progression of endometrial cancer via crosstalk with estrogen receptor α.

Wang J, Bao W, Qiu M, Liao Y, Che Q, Yang T, He X, Qiu H, Wan X.

Oncol Rep. 2014 Mar;31(3):1225-34. doi: 10.3892/or.2014.2982. Epub 2014 Jan 20.

PMID:
24452315
4.

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.

J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.

PMID:
18037662
5.

Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamous cell carcinomas with extensive lymph node metastasis.

Sano M, Aoyagi K, Takahashi H, Kawamura T, Mabuchi T, Igaki H, Tachimori Y, Kato H, Ochiai A, Honda H, Nimura Y, Nagino M, Yoshida T, Sasaki H.

Int J Oncol. 2010 Feb;36(2):321-30.

PMID:
20043065
6.

FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.

Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, Müntener M, Kristiansen G.

Am J Pathol. 2012 Feb;180(2):848-61. doi: 10.1016/j.ajpath.2011.10.021. Epub 2011 Dec 2.

PMID:
22138582
7.

Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.

Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F.

Breast Cancer Res. 2009;11(3):R40. doi: 10.1186/bcr2327. Epub 2009 Jun 23.

8.

FOXA1 represses the molecular phenotype of basal breast cancer cells.

Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA.

Oncogene. 2013 Jan 31;32(5):554-63. doi: 10.1038/onc.2012.62. Epub 2012 Mar 5.

9.

FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer.

Shigekawa T, Ijichi N, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Horm Cancer. 2011 Oct;2(5):286-97. doi: 10.1007/s12672-011-0082-6.

PMID:
21901488
10.

Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.

Ademuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S.

Mod Pathol. 2010 Feb;23(2):270-5. doi: 10.1038/modpathol.2009.172. Epub 2009 Nov 27.

11.

Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO.

Eur J Cancer. 2008 Jul;44(11):1541-51. doi: 10.1016/j.ejca.2008.04.020. Epub 2008 Jun 4.

PMID:
18538561
12.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

13.

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S.

Breast Cancer Res Treat. 2012 Feb;131(3):881-90. doi: 10.1007/s10549-011-1482-6. Epub 2011 Apr 19.

PMID:
21503684
14.

FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer.

Qiu M, Bao W, Wang J, Yang T, He X, Liao Y, Wan X.

BMC Cancer. 2014 Feb 11;14:78. doi: 10.1186/1471-2407-14-78.

15.

Switch in FOXA1 status associates with endometrial cancer progression.

Tangen IL, Krakstad C, Halle MK, Werner HM, Oyan AM, Kusonmano K, Petersen K, Kalland KH, Akslen LA, Trovik J, Hurtado A, Salvesen HB.

PLoS One. 2014 May 21;9(5):e98069. doi: 10.1371/journal.pone.0098069. eCollection 2014.

16.

FOXA1: a transcription factor with parallel functions in development and cancer.

Bernardo GM, Keri RA.

Biosci Rep. 2012 Apr 1;32(2):113-30. doi: 10.1042/BSR20110046. Review.

PMID:
22115363
17.

FoxA1 as a lineage-specific oncogene in luminal type breast cancer.

Yamaguchi N, Ito E, Azuma S, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Tatsuta K, Inoue J, Semba K, Watanabe S.

Biochem Biophys Res Commun. 2008 Jan 25;365(4):711-7. Epub 2007 Nov 26.

PMID:
18039470
18.

Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity.

Potter AS, Casa AJ, Lee AV.

J Cell Biochem. 2012 Jan;113(1):110-21. doi: 10.1002/jcb.23333.

19.

FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.

Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M.

Clin Cancer Res. 2009 Jun 1;15(11):3680-9. doi: 10.1158/1078-0432.CCR-08-3155. Epub 2009 May 26.

20.

FOXA1 as a therapeutic target for breast cancer.

Nakshatri H, Badve S.

Expert Opin Ther Targets. 2007 Apr;11(4):507-14. Review.

PMID:
17373880
Items per page

Supplemental Content

Write to the Help Desk